Product Availability: In Stock (FedEx delivery within 2 business days).
Ordering: To place an order please use Add to Cart button (account not required).
Electroporation Kit for CCRF-CEM Cells (CML Leukemia Cells, CCL-119)
- Electroporation Kit include: electroporation buffer + buffer-specific optimized electroporation protocols
- Preoptimized electroporation protocols are provided for delivery of plasmids (DNA), siRNA, mRNA, and proteins
- Proprietary electroporation buffer formulation mimics cellular cytoplasm composition (superior electropore resealing)
- Certified RNAse- and DNAse-free electroporation buffer
- Effective electroporation delivery and high cell viability provides reproducible electroporation results
- High cell viability and superior cell recovery rates
- Electroporation protocols are provided with with the purchase of the Electroporation Kit
- UPC/GTIN/EAN: 860002089748
Brand: ALTOGEN®, developed and manufactured by Altogen Biosystems
4 mL of electroporation buffer is sufficient for 20 reactions using standard 0.2 cm elecrtoporation cuvette
30 mL of electroporation buffer is sufficient for 150 reactions using standard 0.2 cm elecrtoporation cuvette
Electroporation kit provides 80-95% delivery efficiency of siRNA. Electroporation efficiency was determined by qRT-PCR.
Electroporation Protocol and MSDS:
Electroporation protocols are provided with the purchase of the Electroporation Kit
Download MSDS: [PDF]
CCRF-CEM Cell Line:
The CCRF-CEM cell line was established in 1964 from the peripheral blood of a 4-year-old Caucasian female who suffered from acute lymphoblastic leukemia. These tumorigenic cells exhibit lymphoblast morphology and a T lymphoblast cell type. CCRF-CEM cells positively express CD3 – CD7 antigens, except for CD6. These cells could be useful for transfection experiments to study leukemia. CCRFCEM cells are a human T-cell leukemia cell line that was originally isolated from the peripheral blood of a patient with acute lymphoblastic leukemia. These cells are commonly used as a model system to study the mechanisms underlying T-cell leukemia and to screen potential anti-cancer drugs. CCRF-CEM cells have been extensively studied and characterized, and they are known to exhibit many of the features of T-cell leukemia cells, including rapid proliferation, high levels of cytokine production, and the expression of T-cell surface markers. Researchers use CCRF-CEM cells to investigate the molecular pathways that drive the development and progression of T-cell leukemia, as well as to test the efficacy of potential drugs that may be used to treat the disease. CCRF-CEM cells are a valuable tool in the study of T-cell leukemia and have contributed to advances in our understanding of the disease and the development of new treatments.
Altogen Biosystems is a life sciences company that manufactures over 120 cell type specific and optimized transfection reagents, electroporation buffers, and targeted in vivo delivery kits. Advanced formulation of reagents and optimized electroporation protocols provide highly efficient intracellular delivery of biomolecules (proteins, DNA, mRNA, shRNA and siRNA, and small molecule compounds). Read more about electroporation technology at Altogen’s Transfection Resource.
Altogen Laboratories Contract Research Services:
Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (90+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
- 4 ml (Catalog #6559)
- 30 ml (Catalog #6560)